BPC-157 Dosing Research: What We Know About Minimum Effective Dose and Human Schedules
In Research Protocols, there is much discussion regarding the best cycle for BPC-157. In theory, most researchers agree on:
Administration: Subcutaneous or intramuscular injection
Typical Cycle Length: 8-10 weeks followed by 4-6 week washout
Frequency: 5 days per week, with 2 consecutive rest days (7 days per week okay for 8 week cycle)
Injury-Specific Use: Administer as close to injury site as appropriate OR into abdominal region (best systemic uptake)
- Week 1: 250mcg, 1-3 times per day
- Weeks 2–4: 500mcg, 1-3 times per day
- Weeks 5–8: 750mcg, 1-3 times per day
BPC-157 is one of the most discussed experimental peptides in the recovery, sports performance, and regenerative wellness space. It is often promoted online for injury recovery, gut support, joint comfort, and tissue repair, but the human dosing conversation is much less settled than the marketing makes it sound.
The most important fact is this: there is no FDA-approved human dose for BPC-157, and there is no established minimum effective dose for humans. BPC-157 is not listed in the FDA’s approved drug database, and Operation Supplement Safety states that BPC-157 is an unapproved drug, not a dietary ingredient, and not legally sold as an over-the-counter supplement.
That does not mean BPC-157 has no research behind it. It means the research is not strong enough to create a verified human dosing standard. Most of the evidence behind BPC-157 comes from animal studies, cell studies, small pilot human reports, or clinical trial registrations rather than large, controlled, FDA-reviewed human trials.
What Is BPC-157?
BPC-157 stands for Body Protection Compound 157. It is a synthetic peptide made of 15 amino acids. The compound is often discussed as a “pentadecapeptide,” meaning a peptide made from 15 amino acids. OPSS describes BPC-157 as a laboratory-made synthetic peptide that is commonly promoted for organ protection, wound recovery, tissue repair, gut health, joint health, inflammation, and performance support.
However, those online claims should be treated carefully. OPSS notes that the marketed benefits of BPC-157 have mainly been shown in lab and animal studies, including rats, mice, and dogs. The same source states that the lack of comprehensive human clinical studies means there is little reliable scientific evidence to support its safety or effectiveness in humans.
That makes BPC-157 very different from FDA-approved peptide drugs like semaglutide, tirzepatide, insulin, oxytocin, or bremelanotide. Those drugs went through formal human clinical development and have approved labels, indications, dosing instructions, safety warnings, and manufacturing standards.
Is There a Minimum Effective Dose for BPC-157?
At this point, there is no verified minimum effective dose for BPC-157 in humans.
A “minimum effective dose” means the lowest dose that consistently produces a measurable benefit in a defined patient population. To establish that, researchers would need controlled human trials comparing different doses, placebo groups, clinical endpoints, safety tracking, and follow-up data.
That has not been done at the level needed to create a reliable dosing standard.
For BPC-157, the current human data is too limited. There are small human reports and pilot studies, but they do not establish a general minimum effective dose. A tiny safety study can show that a dose was tolerated in a small number of people, but it cannot prove that the dose is effective, optimal, or safe for broader use.
What Human Dosing Has Actually Been Studied?
The clearest published human safety study found in the literature is a 2025 pilot study on intravenous BPC-157. In that study, two healthy adult participants received 10 mg of BPC-157 infused over one hour on day one, followed by 20 mg infused over one hour on day two. Blood work and vital signs were checked before and after the infusions, and participants were questioned about side effects.
The study reported no measurable effects on the tested biomarkers for the heart, liver, kidneys, thyroid, or blood glucose, and no side effects were reported. But this was only two participants, both of whom had previously received intravenous BPC-157. The authors also stated that future studies are needed to confirm safety in humans.
That matters because a two-person pilot study does not create a dosing recommendation. It only shows what happened in those two people under that specific study design.
There has also been a registered clinical trial for oral BPC-157 under the name PCO-02, with tablets containing 1 mg of BPC-157 or placebo. The trial registration described oral administration over a short study period, but this did not result in an FDA-approved use for BPC-157.
Human Dose Conversions: Micrograms Per Pound
Because BPC-157 does not have an approved human dose, any mcg-per-pound number should be treated as a mathematical conversion only, not a recommended dose.
Here is how the published or registered human exposure amounts translate by body weight:
| BPC-157 amount | 150 lb person | 180 lb person | 200 lb person |
|---|---|---|---|
| 1 mg oral tablet | 6.7 mcg/lb | 5.6 mcg/lb | 5.0 mcg/lb |
| 10 mg IV infusion | 66.7 mcg/lb | 55.6 mcg/lb | 50.0 mcg/lb |
| 20 mg IV infusion | 133.3 mcg/lb | 111.1 mcg/lb | 100.0 mcg/lb |
These numbers are not a dosing protocol. They are simply a way to understand how published or registered human study amounts compare across body weights.
The most conservative interpretation is that the human data gives us studied exposure examples, not a minimum effective dose.
https://pubmed.ncbi.nlm.nih.gov/40131143
What About Common Online BPC-157 Dosing Schedules?
Online BPC-157 protocols often mention daily injections, oral capsules, intranasal use, localized injections, or short “cycles.” The problem is that most of those schedules are not based on FDA-approved labeling or strong human dose-ranging trials.
That distinction matters.
An online protocol may tell people what others are doing. A clinical trial tells researchers what was tested, how it was monitored, what endpoints were measured, and what safety issues appeared. Those are not the same thing.
For BPC-157, there is no FDA-approved schedule for:
Daily injection.
Oral use.
Intranasal use.
Localized injury use.
Gut health use.
Joint use.
Tendon or ligament recovery.
Long-term maintenance.
Because there is no approved schedule, the most accurate way to write about BPC-157 dosing is to say that dosing remains experimental and not standardized.
Why Human Dosing Is Hard to Establish
BPC-157 research is complicated because route of administration may matter. Oral, subcutaneous, intramuscular, intravenous, intranasal, and localized injection routes could produce different exposure patterns.
A dose that is studied orally cannot automatically be treated as equivalent to an injectable dose. A dose used in an animal study cannot be directly converted into a human protocol without proper pharmacokinetic and safety testing.
Peptides can also vary by purity, salt form, stability, sterility, and source. The FDA has cautioned that certain bulk drug substances used in compounding may present significant safety risks, and OPSS specifically notes concerns about compounded BPC-157 products and possible contamination with other substances.
This is one reason BPC-157 dosing content should avoid overconfident claims. The molecule is only one part of the safety question. The product source, manufacturing process, route, sterility, concentration, dosing schedule, and user’s health history all matter.
FDA and Regulatory Status
BPC-157 is not FDA-approved. It is also listed by the World Anti-Doping Agency under S0: Non-Approved Substances, according to OPSS. For tested athletes, that matters because BPC-157 use can create anti-doping risk even if the product is marketed as a wellness or recovery peptide.
The FDA has also scheduled a Pharmacy Compounding Advisory Committee meeting to discuss BPC-157-related bulk drug substances, including BPC-157 free base and BPC-157 acetate, for possible inclusion on the 503A Bulks List. The FDA meeting page lists ulcerative colitis as the reviewed use for BPC-157-related bulk drug substances.
That does not mean BPC-157 is approved. It means the regulatory conversation is still active.
What Can Be Said Factually About BPC-157 Dosing?
A factual and careful summary would be:
BPC-157 has no FDA-approved human dose.
There is no established minimum effective dose in humans.
Human research is limited.
A registered oral study used 1 mg tablets.
A very small published IV pilot study used 10 mg on day one and 20 mg on day two in two adults.
Those amounts can be converted into mcg per pound, but the conversion is not a recommendation.
Most marketed BPC-157 claims rely heavily on animal, lab, or anecdotal evidence.
Safety, effectiveness, ideal route, treatment duration, and long-term risks remain uncertain.
That is the most defensible position based on the available sources.
Why “Minimum Effective Dose” Should Be Treated Carefully
The phrase “minimum effective dose” sounds precise, but with BPC-157 it can easily become misleading.
For FDA-approved drugs, the minimum effective dose is usually developed through dose-ranging trials. Researchers compare multiple doses against placebo, measure outcomes, track side effects, and identify a dose that balances benefit and risk.
BPC-157 does not yet have that type of evidence base.
A 1 mg oral tablet may be a studied amount. A 10 mg or 20 mg IV infusion may be a studied amount. But neither establishes the lowest effective dose for injury recovery, gut health, pain, tissue repair, or any other outcome.
The honest answer is that the minimum effective dose is currently unknown.
Key Points
BPC-157 is a heavily marketed experimental peptide, but human dosing is not standardized. The available human data shows isolated exposure examples, not an FDA-approved protocol.
The best way to discuss BPC-157 dosing is to separate three things:
What has been studied.
What has been claimed.
What has been proven.
So far, the human dosing evidence is limited. A registered oral study used 1 mg tablets, and a small IV pilot study tested 10 mg and 20 mg infusions in two adults. Those numbers can be converted into mcg per pound for educational comparison, but they should not be presented as a recommended dose or schedule.
Until larger, controlled human trials are available, BPC-157 dosing remains experimental, and any discussion of “minimum effective dose” should be framed as unknown rather than established.